MYNZ
Mainz Biomed NV
$
1.720
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
1.760
Open
1.520
VWAP
1.66
Vol
597.63K
Mkt Cap
7.87M
Low
1.5175
Amount
994.34K
EV/EBITDA(TTM)
--
Total Shares
21.89M
EV
2.73M
EV/OCF(TTM)
--
P/S(TTM)
1.59
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
250.00K
+37.61%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Mainz Biomed N.V. (MYNZ) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -24.06%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-24.06%
In Past 3 Month
1 Analyst Rating
713.95% Upside
Wall Street analysts forecast MYNZ stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MYNZ is 14.00 USD with a low forecast of 14.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
713.95% Upside
Current: 1.720
Low
14.00
Averages
14.00
High
14.00
713.95% Upside
Current: 1.720
Low
14.00
Averages
14.00
High
14.00
Maxim Group
Michael Okunewitch
Strong Buy
Initiates
$14
2025-02-14
Reason
Maxim Group
Michael Okunewitch
Price Target
$14
2025-02-14
Initiates
Strong Buy
Reason
Maxim initiated coverage of Mainz Biomed with a Buy rating and $14 price target.
HC Wainwright & Co.
Yi Chen
Strong Buy
to
Hold
Downgrades
n/a
2024-11-25
Reason
HC Wainwright & Co.
Yi Chen
Price Target
n/a
2024-11-25
Downgrades
Strong Buy
to
Hold
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Mainz Biomed NV (MYNZ.O) is -0.38, compared to its 5-year average forward P/E of -2.72. For a more detailed relative valuation and DCF analysis to assess Mainz Biomed NV 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-2.72
Current PE
-0.38
Overvalued PE
-0.05
Undervalued PE
-5.39
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
59.55
Current PS
4.64
Overvalued PS
141.52
Undervalued PS
-22.42
Financials
Annual
Quarterly
FY2023Q4
214.76K
Total Revenue
FY2023Q4
-6.59M
Operating Profit
FY2023Q4
-5.18M
Net Income after Tax
FY2023Q4
-0.27
EPS - Diluted
FY2023Q4
-4.92M
Free Cash Flow
FY2023Q4
62.74
Gross Profit Margin - %
FY2023Q4
-2.66K
FCF Margin - %
FY2023Q4
-2.41K
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
MYNZ News & Events
Events Timeline
2025-08-13 (ET)
2025-08-13
08:25:52
Mainz Biomed receives Swiss regulatory approval to market ColoAlert
2025-07-23 (ET)
2025-07-23
08:20:53
Mainz Biomed, CARE announce collaboration agreement
2025-07-15 (ET)
2025-07-15
08:07:16
Mainz Biomed reviews accomplishments for first half of 2025
Sign Up For More Events
Sign Up For More Events
News
9.0
08-13NewsfilterPinnedMainz Biomed Receives Swiss Regulatory Approval to Market ColoAlert®
8.5
08-04NewsfilterMainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants
9.0
07-15NewsfilterMainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition
Sign Up For More News
People Also Watch
SQFT
Presidio Property Trust Inc
5.290
USD
+4.96%
ICU
SeaStar Medical Holding Corp
0.727
USD
-0.41%
MSN
Emerson Radio Corp
0.447
USD
+1.36%
APLM
Apollomics Inc
5.800
USD
+0.35%
BIAF
bioAffinity Technologies Inc
0.280
USD
+2.19%
SGMA
SigmaTron International Inc
0
USD
-0.33%
GVH
Globavend Holdings Ltd
5.180
USD
-0.19%
AYTU
Aytu Biopharma Inc
2.290
USD
+1.78%
ZONE
CleanCore Solutions Inc
3.930
USD
0.00%
FAQ
What is Mainz Biomed NV (MYNZ) stock price today?
The current price of MYNZ is 1.72 USD — it has increased 17.01 % in the last trading day.
What is Mainz Biomed NV (MYNZ)'s business?
What is the price predicton of MYNZ Stock?
What is Mainz Biomed NV (MYNZ)'s revenue for the last quarter?
What is Mainz Biomed NV (MYNZ)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Mainz Biomed NV (MYNZ)'s fundamentals?
How many employees does Mainz Biomed NV (MYNZ). have?